Key result
Study evaluating metabolic syndrome as a predictor of contrast-induced nephropathy reports no results.
Why the study?
Does metabolic syndrome increase the risk of contrast-induced nephropathy in patients undergoing coronary angiography?
Observational (n=310)
No
Does metabolic syndrome increase the risk of contrast-induced nephropathy in patients undergoing coronary angiography?
No takes yet. Share an insight, caveat, or question.
Metabolic syndrome may raise CIN risk after elective PCI in nondiabetics; leaves open whether targeted prevention improves outcomes.
Alyavi et al. (2017) conducted an observational in Metabolic syndrome in patients undergoing coronary angiography (n=310). Metabolic syndrome vs. No metabolic syndrome was evaluated on Contrast-induced nephropathy (CIN). The abstract describes a study evaluating metabolic syndrome as a predictor of contrast-induced nephropathy in 310 patients undergoing coronary angiography, but reports no results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: